{
    "type": "ETF",
    "ucits": true,
    "replication_method": "physical",
    "leverage": false,
    "derivatives": false,
    "swaps": false,
    "inverse": false,
    "complex_factors": [],
    "classification": "non-complex",
    "supporting_data": "The VanEck Bionic Engineering UCITS ETF is classified as non-complex under MiFID II based on the following analysis:1. **Replication Method**: The fund uses physical (full) replication as confirmed in the fact sheet, investing directly in the underlying equity securities of the MVIS Global Bionic Healthcare ESG Index. There is no mention of synthetic replication or swap agreements in the KIID or fact sheet.2. **Derivative Usage**: While the KIID mentions the possibility of using derivatives (futures, options, swaps) for replication purposes, the fact sheet explicitly states the fund uses physical replication. The derivatives mentioned in the KIID are likely for efficient portfolio management (e.g., hedging) rather than as an inherent part of the strategy. There is no evidence of leverage, inverse exposure, or complex derivative structures.3. **Underlying Assets**: The fund invests in liquid, transparent equity securities of companies in the bionic engineering sector. There is no exposure to complex or illiquid assets like contingent convertible bonds (CoCos), AT1 bonds, or CLOs.4. **Risk Profile**: The fund's risk profile is straightforward, with risks primarily related to equity market fluctuations and sector concentration. The risk rating of 7 (on a scale of 1-7) is consistent with the volatility of the underlying equities and does not indicate complexity.5. **UCITS Compliance**: The fund is UCITS-compliant, which inherently limits the use of complex strategies and derivatives. UCITS funds are subject to strict regulations that restrict leverage and derivative usage, making them generally suitable for retail investors.6. **Counterarguments and Override**: While the KIID mentions the possibility of using derivatives, the fact sheet's explicit confirmation of physical replication and the absence of complex strategies or leverage in the documentation override any potential concerns. The fund's structure and strategy are transparent and easily understandable for retail investors.7. **Confidence Score**: 90% - The analysis is supported by clear evidence from the KIID, PRIIPs KID, and fact sheet, with no conflicting information suggesting complexity.",
    "confidence": 90
}